Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vincent Alcazer1, Christophe Delenda2, Laurent Poirot2

  • 1INSERM U1052, Centre de Recherche en Cancérologie, 69008 Lyon, France; Hospices civils de Lyon, Service d'hématologie, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology.

Blood·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia.

HemaSphere·2025
Same author

The pivotal role of immune functional assays in deciphering immune function alterations.

Clinical and experimental immunology·2025
Same author

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

Journal for immunotherapy of cancer·2025
Same author

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model.

Leukemia·2025
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Chimeric Antigen Receptor (CAR) T-cell therapy shows promise for solid tumors, overcoming challenges like antigen heterogeneity and immunosuppression. Optimized CAR T-cell designs are key to improving treatment efficacy and expanding applications.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric Antigen Receptor (CAR) T-cells demonstrate significant efficacy in hematologic malignancies.
  • Their application in solid tumors is limited by factors such as antigen heterogeneity, immunosuppressive tumor microenvironment, and poor T-cell persistence.

Purpose of the Study:

  • To review the challenges and perspectives of CAR T-cell therapy in solid tumors.
  • To explore strategies for enhancing CAR T-cell efficacy against solid tumors.

Main Methods:

  • Review of current research on CAR T-cell therapy in solid tumors.
  • Discussion of various approaches to overcome resistance mechanisms.

Main Results:

  • Solid tumors present unique challenges including heterogeneous antigen expression, immunosuppressive microenvironments, and homing/trafficking issues.
Keywords:
CARCibleCombinaisonCombinationImmunosuppressionOptimisationOptimizationSolid tumorsTargetTumeurs solides

Related Experiment Videos

  • Several strategies are being investigated to improve CAR T-cell performance, including bispecific CARs, logic gates, combination therapies, and armored CAR T-cells.

    • Conclusions:

    • Optimized CAR T-cell designs hold potential for therapeutic breakthroughs in solid tumors.
    • CAR T-cell therapy may become a viable option for cold tumors and those lacking MHC class I expression.